Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyBlue Cross Blue Shield - Alabama Hemophilia Prior …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - AlabamaPolicy N/A

    PEEHIP Hemophilia Product Prior Authorization Form and Documentation Checklist

    Customize your policy alerts

    Sign up for all blue cross blue shield - alabama policy alerts

    Know when blue cross blue shield - alabama releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization form and documentation checklist for hemophilia and related clotting factor products for members covered by Blue Cross and Blue Shield of Alabama (PEEHIP). Affects prescribers, dispensing pharmacies, and treating facilities requesting coverage for listed products.

    Policy Summary
    PayerBlue Cross Blue Shield - Alabama
    PolicyPEEHIP Hemophilia Product Prior Authorization Form
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFax the completed prior authorization form and all supporting documentation, including progress notes and inhibitor testing results, to 1-866-606-6021.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30+listed hemophilia products on form
    12clinical/administrative sections on the form

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Fax 1fax number for submission

    Coverage and Submission Criteria

    Required submission criteria

    Authorization requests should include documentation that all applicable items below have been provided.

    Basic administrative and clinical information: Completed patient, provider, and pharmacy information; insurance details; indication (select diagnosis); and ICD-10 code.

    see chunks 8

    Clinical severity and testing: Severity classification (Mild/Moderate/Severe), baseline factor level with date, desired target factor level, and inhibitor testing status with results (e.g., Bethesda assay).

    see chunks 8 and 9

    Type of use: Request indicates one or more of: episodic use, prophylaxis, acute bleeding episode, dental or surgical prophylaxis (include procedure dates), place of administration, and dosing instructions/quantities requested.

    see chunk 8

    Prior therapies or contraindications when applicable: For von Willebrand disease: documentation of desmopressin trial or documented contraindication; for Glanzmann's Thrombasthenia: documentation of platelet transfusion trial and response; for patients who received prior factor products: history of prior product and reason for switch; for minimally treated patients (< 50 exposure days) include plan/frequency for inhibitor testing.< 50 exposure days

    see chunks 8 and 9

    Immune tolerance and PK information: Documentation of prior Immune Tolerance Induction (ITI) if performed (dates, duration, response) and pharmacokinetic (PK) testing results when available.

    see chunk 9

    Retrospective or utilization reconciliation details: If retrospective request or for utilization reconciliation, provide number and dates of doses used, number of doses/units on hand, dose (IU), and total amount used.

    see chunk 8 and 10

    Acute bleed details (when applicable): For acute bleeding episodes provide location and type of bleed (minor/moderate/major), start and end dates, number of doses used, dose (IU), and total amount used (IU).

    see chunk 10

    The form does not list any explicit coverage exclusions. It functions as a clinical authorization and documentation checklist, and no section on the form enumerates items that are specifically excluded from coverage.

    This document is a prior authorization/data collection form for hemophilia and related clotting‑factor products; it is intended to gather clinical and administrative information (patient/provider details, progress notes, lab results) to support an authorization decision rather than to serve as a standalone coverage policy statement.

    Diagnosis and Coding Details

    Diagnosis Codes (ICD-10)ICD-10
    ICD-10ICD-10 code field provided for primary diagnosis (specific codes not listed on form)
    Exposure days
    Exposure days threshold< 50 exposure days for 'minimally treated' patients
    ImplicationMinimally treated patients (< 50 exposure days) require a plan for more frequent inhibitor testing; form asks: 'how often will inhibitor testing be performed?'
    Context for prior product switchApplies when patient previously received a different factor product; used to guide monitoring frequency

    Provider Responsibilities and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for the hemophilia products listed on the Hemophilia Product Prior Authorization Form. Complete and submit the form in its entirety and fax the form and all required attachments to 1-866-606-6021. All lab results must be faxed in with the request.

    • Affected products: Helixate FS; Alphanate; Hemlibra; Wilate; Kogenate FS; BeneFIX; Idelvion; Novoeight; Ixinity; Vonvendi; Recombinate; Rixubis; Afstyla; Xyntha; Alprolix; Adynovate; Coagadex; Eloctate; Corifact; Feiba; Feiba NF; NovoSeven; RT Hemofil M; Koate-DVI; Monoclate-P; Nuwiq; Advate; Obizur; Humate-P; AlphaNine SD; Mononine; Bebulin; Kovaltry; Profilnine; Rebinyn; Tretten
    • Fax number for submission: 1-866-606-6021
    Documentation Required

    Prior Therapy Documentation Required

    Document prior therapy trials when applicable. For von Willebrand disease (VWD) include documentation of a trial of desmopressin or a contraindication to desmopressin with the reason. For Glanzmann's thrombasthenia include documentation of platelet transfusion trials and response. For patients previously treated with a different factor product, indicate prior product and reason for switching. Include dates and responses for prior immune tolerance induction (ITI) if applicable.

    Policy Form Background

    The form collects detailed clinical data for congenital and acquired bleeding disorders, including diagnoses such as Congenital Hemophilia A/B, Acquired Hemophilia A, von Willebrand disease, factor deficiencies, and Glanzmann's Thrombasthenia. It requests information on disease severity and history (e.g., prior bleeds, number of spontaneous joint bleeds), laboratory results (factor levels, inhibitor testing such as the Bethesda assay), prior treatments and trials (desmopressin for VWD, platelet transfusions for Glanzmann's), treatment status (naïve versus experienced), and additional details for acute bleeding or procedural prophylaxis.

    Definitions and Clinical Categories

    Severity of Disease
    Mild6% to 25% factor level
    Moderate1% to 5% factor level
    Severe< 1% factor level
    Inhibitor testing
    Type of testTesting for neutralizing antibodies to factor products (e.g., Bethesda inhibitor assay)
    Documentation requestedAttach inhibitor test results to the request form (asks: 'are documentations of inhibitor tests attached?')
    Immune tolerance historyIndicate prior Immune Tolerance Induction (ITI) status with date, duration, and patient response
    Policy Summary
    PayerBlue Cross Blue Shield - Alabama
    PolicyPEEHIP Hemophilia Product Prior Authorization Form
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFax the completed prior authorization form and all supporting documentation, including progress notes and inhibitor testing results, to 1-866-606-6021.
    SourceLink
    On This Page
    Coverage and Submission CriteriaDiagnosis and Coding DetailsProvider Responsibilities and Submission RequirementsPolicy Form BackgroundDefinitions and Clinical Categories
    • VWD: desmopressin trial documentation or documented contraindication and reason
    • Glanzmann's Thrombasthenia: platelet transfusion trial dates and response
    • Prior factor product: name, dates, and reason for switching
    • Previous ITI: dates, duration, and patient response
    Documentation Required

    Required Documentation for Submission

    Required documentation must accompany the prior authorization form. Incomplete requests risk denial or return-to-provider for additional information.

    • Completed Hemophilia Product Prior Authorization Form (all fields)
    • Patient demographics and provider/pharmacy contact information
    • Progress notes and/or bleeding diaries documenting number and location of bleeds in the past 12 months
    • Relevant laboratory results (baseline and most recent factor levels, dates, desired target levels)
    • Inhibitor testing results (e.g., Bethesda assay) and documentation of frequency of inhibitor testing for minimally treated patients (<50 exposure days)
    • Pharmacokinetic (PK) test results, if performed
    • Dosing details: dose (IU), number of doses requested, total dose requested, and dosing instructions
    • Procedure information for surgical or dental prophylaxis (type and date of procedure) and place of administration
    • For retrospective requests, indicate retrospective status on the form
    Denial Risk

    Missing Documentation — Denial Risk

    Requests may be denied or returned to the provider if the form is incomplete or required attachments are missing.

    • Missing or incomplete prior authorization form
    • Absence of progress notes or bleeding diaries
    • Missing lab results or inhibitor testing documentation (e.g., Bethesda assay)
    • Missing prior therapy documentation (desmopressin trial for VWD, platelet transfusion for Glanzmann's, prior product trials, ITI details)
    Minimally treated monitoringFor patients with < 50 exposure days, form requests plan for frequency of inhibitor testing